Effect of gonadotropin-releasing hormone agonist on a uterine arteriovenous malformation.
BACKGROUND
The effect of gonadotropin-releasing hormone agonist (GnRHa) on uterine arteriovenous malformations (AVM) is not well known.


METHODS
A 37-year-old woman with a previous cesarean was diagnosed as having a uterine AVM after a spontaneous abortion with massive vaginal bleeding. The AVM decreased in size from 5.1 x 3.8 cm to 1.4 x 1.0 cm after 6 months of therapy with a GnRHa. Uterine artery embolization conducted after the GnRH therapy resulted in complete disappearance of the AVM. The patient's menstrual cycles and ovulation resumed 3 months after uterine artery embolization.


CONCLUSIONS
Gonadotropin-releasing hormone agonist therapy reduced the size of the uterine AVM. Thus, GnRHa therapy may be useful for uterine AVM in situations where uterine artery embolization must be postponed.
Morikawa
Mamoru
M
Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. mmamoru@med.hokudai.ac.jp
Yamada
Takashi
T
Yamada
Hideto
H
Minakami
Hisanori
H
D000022:Abortion, Spontaneous; D000328:Adult; D001165:Arteriovenous Malformations / Q000175:diagnosis* / Q000628:therapy*; D006063:Chorionic Gonadotropin / Q000097:blood; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D011247:Pregnancy; D014463:Ultrasonography; D014592:Uterine Hemorrhage / Q000628:therapy; D014599:Uterus / Q000098:blood supply*
D006063:Chorionic Gonadotropin; D016729:Leuprolide